Investors

/Investors
Investors 2019-01-03T10:17:20+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

3.22
-0.02 (-0.62%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :6,230
Date :03-22-2019

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at BIO CEO & Investor Conference

February 6th, 2019|Comments Off on Oramed to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate [...]

Oramed Initiates Phase I Oral GLP-1 Study Under IND

January 22nd, 2019|Comments Off on Oramed Initiates Phase I Oral GLP-1 Study Under IND

JERUSALEM, Jan. 22, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its [...]

Oramed Pharmaceuticals’ CEO Letter to Shareholders

January 15th, 2019|Comments Off on Oramed Pharmaceuticals’ CEO Letter to Shareholders

JERUSALEM, Jan. 15, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) Dear Shareholders, We opened the year 2019 with the announcement of our receipt of a $3 million milestone payment from our [...]

Oramed Receives Additional $3 Million Milestone Payment from HTIT

January 9th, 2019|Comments Off on Oramed Receives Additional $3 Million Milestone Payment from HTIT

Totaling $33 M in payments from HTIT received to date JERUSALEM, Jan. 9, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, [...]